Revalesio Corporation is a clinical stage pharmaceutical company partnering with international leaders in biomedical research to develop drugs to safely treat neurodegenerative diseases.
Revalesio’s proprietary application of fluid cavitation via turbulent Taylor-Couette-Poiseuille (TCP) flow has resulted in groundbreaking discoveries in the application of physical chemistry to the treatment of disorders related to mitochondrial dysfunction.
